4
Changes in Ownership
Fulcrum Therapeutics, Inc. Filed Acc 0000899243-22-021250
Director sold 66,622 shares at an average $8.00 ($532,810)
- Director acquired 66,622 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Gould Robert J · Director
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-06-02 | Exercise or conversion : show line 1 in the form | +16,689 | $7.84 | $130,842 | 523,319 | D |
| 2022-06-02 | Sale : show line 2 in the form | −16,689 | $7.92 | $132,162 | 506,630 | D |
| 2022-06-03 | Exercise or conversion : show line 3 in the form | +25,551 | $7.84 | $200,320 | 532,181 | D |
| 2022-06-03 | Sale : show line 4 in the form | −25,551 | $7.95 | $203,056 | 506,630 | D |
| 2022-06-06 | Exercise or conversion : show line 5 in the form | +24,382 | $7.84 | $191,155 | 531,012 | D |
| 2022-06-06 | Sale : show line 6 in the form | −24,382 | $8.10 | $197,592 | 506,630 | D |
| Open-market sales · 66,622 sh · avg $8.00 · $532,810 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-06-02 | Exercise or conversion : show line 7 in the form Stock Option (right to buy) | −16,689 | 207,891 | D |
| 2022-06-03 | Exercise or conversion : show line 8 in the form Stock Option (right to buy) | −25,551 | 182,340 | D |
| 2022-06-06 | Exercise or conversion : show line 9 in the form Stock Option (right to buy) | −24,382 | 157,958 | D |
Loading xslF345X03/doc4.xml…